Improved Operating Efficiency
Achieved notable improvements in operating efficiency, particularly in peripheral operations, with a significant reduction in operating costs and cash needs.
Strategic Realignment and Cost Savings
Implemented a cost savings program that reduced overall headcount by 24%, resulting in improved efficiency in gross margin and revenue per sales head.
Advancements in Coronary Program
Substantial progress on developing the first coronary product application, with successful completion of Phase III verification and validation testing for FDA IDE application.
Partnership with Zylox-Tonbridge
Strategic partnership for market access in China and cost-effective manufacturing, with regulatory filings expected by end of year and manufacturing scale-up anticipated by mid-2025.
Improved Financial Performance
Gross margin increased to 26% from 20% in the previous quarter. Operating expenses decreased to $4.1 million from $4.5 million, and net loss improved by 15% compared to the previous quarter.